Next generation live-attenuated influenza vaccine platforms

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Influenza virus poses a significant global health burden due to seasonal epidemics and pandemics.
• Current influenza vaccines offer protection but are limited by viral antigenic drift, necessitating improved strategies.
• Effective control relies on vaccines, yet existing ones face challenges with evolving influenza strains.

Purpose of the Study:

• To review live-attenuated influenza virus vaccine (LAIV) platforms for universal vaccine development.
• To propose key considerations for designing a rational universal influenza vaccine.
• To address the need for broadly reactive antibodies against influenza.

Main Methods:

• Review of scientific literature on live-attenuated influenza virus vaccines (LAIVs).
• Analysis of strategies for inducing broadly reactive and cross-protective immune responses.
• Evaluation of LAIV platforms, including those based on NS segment truncation.

Main Results:

• Live-attenuated influenza virus vaccines (LAIVs) are investigated for their potential to induce durable, cross-protective immunity.
• LAIVs based on NS segment truncation show promise as effective vaccine candidates.
• Current universal vaccine efforts struggle to induce broadly reactive antibodies for long-lasting protection.

Conclusions:

• Further focus on LAIV development platforms is essential for creating a universal influenza vaccine.
• Live-attenuated influenza virus vaccines (LAIVs) represent a promising strategy for achieving broad and durable protection.
• Rational design of universal influenza vaccines requires addressing the induction of broadly reactive antibodies.